PT-141 Dosing Protocol: Bremelanotide Research Guide
Also known as: Bremelanotide, Vyleesi, MC4R Sexual Wellness Peptide
Studied in published research — not a medical recommendation. Primary protocol (Standard Dosing Protocol): 1.75 mg, As needed, minimum 45 minutes before sexual activity.
As needed, minimum 45 minutes before sexual activity
FDA-approved dosing for female hypoactive sexual desire disorder
Subcutaneous (abdomen or thigh)
Human clinical trials or FDA-approved formulation exists
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 2 doses in the vial at the low end.
Save PT-141 (Bremelanotide) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
PT-141 (Bremelanotide) supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Melanocortin Agonist?
A compound that activates melanocortin receptors (MC1R-MC5R) in the body. These receptors control pigmentation, sexual arousal, appetite, and inflammation. PT-141 (Bremelanotide) activates MC4R for sexual function. Melanotan 2 activates MC1R for tanning. Both are synthetic analogs of alpha-MSH.
PT-141 (Bremelanotide) is the same active compound as Vyleesi (Palatin Technologies). FDA approved for: Hypoactive sexual desire disorder (premenopausal women).
Bottom Line Up Front
PT-141 (Bremelanotide) is an FDA-approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women. It works centrally in the brain to increase sexual desire, unlike Viagra which works on blood flow. Nausea is the most common side effect (40%).
Sexual desire disorder in women, erectile dysfunction in men
General libido enhancement in healthy individuals
Vyleesi (Palatin Technologies)
23 (21 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. PT-141 (Bremelanotide) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
PT-141 is a synthetic melanocortin receptor agonist primarily used for treating sexual dysfunction in both men and women. Unlike PDE5 inhibitors (Viagra/Cialis), it works centrally in the brain to increase sexual desire and arousal through melanocortin pathways rather than vascular mechanisms.
Mechanisms of Action
- Activates melanocortin receptors (MC1R, MC4R) in the hypothalamus
- Increases dopamine release in the medial preoptic area
- Stimulates sexual arousal pathways without affecting blood pressure
- 100% bioavailable via subcutaneous route
Research Protocols
Summaries of published research. For educational purposes only.
HPG Axis & Neuroendocrine Hormone Biomarker Panel (PT-141 (Bremelanotide))
Track hypothalamic-pituitary-gonadal (HPG) pulsatility, gonadotropins, and sex-steroid balance before and during neuroendocrine peptide protocols.
Total & Free Testosterone (LC/MS-MS)
Day 0 + Wk 6–8Why track at baseline: Establishes baseline Leydig/ovarian androgen synthesis prior to GnRH or Kisspeptin stimulation.
Week 6–8 check: Verify preservation or restoration of endogenous Free & Total Testosterone.
LH (Luteinizing Hormone) & FSH
Day 0 + Wk 6–8Why track at baseline: Directly measures anterior pituitary gonadotrope responsiveness (critical for Kisspeptin-10 & Gonadorelin).
Week 6–8 check: Confirm pulsatile LH/FSH maintenance without pituitary GnRH receptor desensitization.
Sensitive Estradiol (E2, LC/MS) & SHBG
Day 0 + Wk 6–8Why track at baseline: Evaluates aromatase conversion and sex-hormone binding capacity affecting bioavailable hormone ratios.
Week 6–8 check: Maintain balanced Estradiol-to-Testosterone ratio and stable SHBG.
Prolactin, CBC / Hematocrit & CMP
Day 0 + Wk 6–8Why track at baseline: Rules out hyperprolactinemia (which suppresses GnRH/libido) and tracks systemic metabolic health.
Week 6–8 check: Confirm normal Prolactin (<15 ng/mL) and healthy blood viscosity/liver markers.
Related Studies
We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations). Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.
Limitations: No placebo control reported. Review article — no new primary data.
Clinicians must discern important distinctions between flibanserin, bremelanotide, and other agents when managing premenopausal HSDD. Further research with the most suitable clinical endpoints and consideration of patient factors are crucial before widespread adoption of flibanserin and bremelanotide.
Limitations: No placebo control reported. Review article — no new primary data.
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Human StudySeveral other continuous and categorical outcomes generated modest apparent benefits, though nearly all of these outcomes were likely derived post-hoc. Across RECONNECT trial data from two prior publications and the current study, bremelanotide's benefits are statistically modest and limited to outcomes for which scant evidence of validity among women with HSDD exists.
Limitations: No placebo control reported. Review article — no new primary data.
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
Human StudyAlthough data from clinical trials demonstrated a significant change in validated questionnaires, the overall clinical benefit appears to be modest. However, these results should be interpreted in the light of the dramatic challenges in conducting well-designed clinical trials for female sexual dysfunction, due to the significant placebo effect of pharmacotherapy, and the frequent use of outcome measures that are likely to be highly susceptible to expectation biases, such as long periods of recall of sexual and emotional response.
Limitations: Review article — no new primary data.
These approvals have also renewed excitement in the development of therapeutics targeting the melanocortin system. Here, we review the anatomy and function of the melanocortin system, discuss progress and challenges in developing melanocortin receptor-based therapeutics, and outline potential metabolic and behavioural disorders that could be addressed using pharmacological agents targeting these receptors.
Limitations: No placebo control reported. Review article — no new primary data.
Because bremelanotide is a cyclic peptide molecule with a molecular weight of 1025, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, bremelanotide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Limitations: No placebo control reported. Review article — no new primary data.
Studies showed improvements in desire, arousal, and orgasm scores when 1.75 mg of bremelanotide was administered before sexual activity compared to a placebo. Bremelanotide is a promising way to treat HSDD.
Limitations: Animal study only — human translation uncertain. Review article — no new primary data.
Animal studies suggest that bremelanotide may affect female sexual desire by activating presynaptic MC4Rs on neurons in the mPOA of the hypothalamus, leading to increased release of DA, an excitatory neurotransmitter that increases sexual desire. This review presents what is known about the mechanism of action of bremelanotide in the context of treating HSDD.
Limitations: No placebo control reported. Review article — no new primary data.
The clinical development program comprised 3500 subjects in 43 completed studies. In the phase 3 studies, subjects took bremelanotide for up to 18 months.
Limitations: Standard limitations apply. Check original paper for full discussion.
Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; updates on efficacy and safety of vaginal estrogen for genitourinary syndrome of menopause and bremelanotide for HSDD; removal of flibanserin alcohol REMS; and development of new technology to enhance bioavailability and brain delivery of treatments. The DSM-5 revision combining HSDD and FSAD into one diagnostic category is a less accurate characterization of these separate disorders and may hinder access to demonstrated effective treatments for the women with these conditions.
Limitations: No placebo control reported. Review article — no new primary data.
The last decade has seen an increase in the number and type of pharmacologic treatment options for dysfunction primarily associated with menopause and hypoactive sexual desire disorder. Recent publications and systematic reviews have strengthened the safety data of existing FDA-approved medications as well as off-label therapies.
Limitations: No placebo control reported. Review article — no new primary data.
In Study A, 27 of 30 bremelanotide subjects (90.0%) completed the trial and exhibited a significantly greater reduction in body weight after 16 days versus placebo [least squares mean difference (95% CI), -1.3 (-1.9 to -0.8) kg; p < .0001]. Mean caloric intake in bremelanotide subjects was decreased versus placebo, with a magnitude of reduction of approximately 400 kcal/day throughout Study A (p < .01).
Limitations: Standard limitations apply. Check original paper for full discussion.
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Human StudyAmong 1202 patients included in the integrated and subgroup analyses, bremelanotide achieved statistically significant improvements in measures of increased desire and decreased distress associated with low desire across all age, weight, and BMI subgroups, and all baseline bioavailable testosterone quartiles, with few exceptions. Bremelanotide was further associated with statistically significant increases in reported sexual desire (p < 0.05) in patients not taking hormonal contraceptives, and with a numerical advantage in those taking hormonal contraceptives.
Limitations: Standard limitations apply. Check original paper for full discussion.
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.
Human StudyThe 2 recently approved medications for HSDD, flibanserin and bremelanotide, are reviewed as well as off-label treatments. Overall, HSDD represents a common yet likely underrecognized disorder that midwives and other health care providers who care for women across the life span are in a unique position to address.
Limitations: No placebo control reported. Review article — no new primary data.
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.
Human StudyBremelanotide, with even weaker efficacy, capitalised on the regulatory precedent set by the approval of flibanserin. Reconsideration of regulatory decisions to approve these drugs is in order, as well as a broader examination of how future regulatory decisions can better address conflicts of interest and clinically meaningful benefit.
Limitations: No placebo control reported. Review article — no new primary data.
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.
Human StudyBremelanotide's modest benefits on incompletely reported post-hoc measures of questionable validity in combination with participants substantially preferring to take placebo suggest that the drug is generally not useful. Kingsberg et al.'s data reporting and measurement practices were incomplete and lacked transparency.
Limitations: Review article — no new primary data.
Because of the validity of a dilution QC that showed accurate quantification of 10-fold diluted plasma samples (accuracy 99.4 %, precision < 6 %), the assay is suitable for bremelanotide quantification in its effective concentration range up to 100,000 pg/mL. The ultra-sensitive assay was applied to the quantification of bremelanotide plasma concentrations after oral administration to beagle dogs, which indicated minimal oral absorption.
Limitations: Animal study only — human translation uncertain.
Bremelanotide: First Approval.
Human StudyBremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor (thought to be important for sexual function), giving it the potential to modulate brain pathways involved in sexual response. This article summarizes the milestones in the development of bremelanotide leading to this first regulatory approval.
Limitations: No placebo control reported. Review article — no new primary data.
Bremelanotide is a subcutaneous injection that can be administered as needed approximately 45 minutes prior to sexual activity. Bremelanotide is safe and has limited drug-drug interactions, including no clinically significant interactions with ethanol.
Limitations: No placebo control reported. Review article — no new primary data.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Human StudyStudy 301 began on January 7, 2015, and concluded on July 26, 2016. Study 302 began on January 28, 2015, and concluded on August 4, 2016.
Limitations: Standard limitations apply. Check original paper for full discussion.
This review discusses investigations of melanocortin agonists for the treatment of sexual dysfunction with emphasis on proposed sites and mechanisms of action in the central nervous system that appear to be involved in melanocortinergic modulation of sexual function. Current research validates use of melanocortinergic agents for the treatment of both male and female sexual dysfunction.
Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported. Review article — no new primary data.
More women reported moderate or high sexual desire following bremelanotide treatment vs. placebo (P = 0.0114), and a trend toward more positive responses regarding feelings of genital arousal occurred after bremelanotide compared with placebo (P = 0.0833).
Limitations: Preliminary/pilot study — needs larger trials.
PT-141 Palatin.
Human StudyBremelanotide is a parenterally administered melanocortin receptor agonist that is used to treat female hypoactive sexual desire disorder. Bremelanotide has been reported to cause mild serum enzyme elevations during therapy and has been implicated in rare instances of clinically apparent acute liver injury.
Limitations: No placebo control reported. Review article — no new primary data.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Do not combine with PDE5 inhibitors (Viagra, Cialis) - risk of severe hypotension
- •Nausea occurs in ~40% of users, lasting 2+ hours
- •Contraindicated in uncontrolled hypertension or cardiovascular disease
- •May cause flushing and increased body temperature
- •Not for use in pregnancy
Where to get PT-141 (Bremelanotide), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy PT-141 (Bremelanotide): best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Ascension Peptides — $2.45/mg (10mg Lyophilized Vial, $24.50)
- 2. Pure Peptides — $3.70/mg (20mg vial, $74.00)
- 3. Polaris Peptides — $4.00/mg (10mg vial, $40.00)
Where is the cheapest place to buy PT-141 (Bremelanotide)?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $2.45/mg (10mg Lyophilized Vial, $24.50 after the 50% new-customer partner-link discount). We compared 11 US suppliers with live, checked prices.
How much does PT-141 (Bremelanotide) cost per mg?
Verified US domestic prices currently range from $2.45/mg to $9.59/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is PT-141 (Bremelanotide) approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Trusted Voices
X/Twitter accounts discussing this peptide
Related Peptides
More hormonal peptides
CJC-1295 (No DAC / Mod GRF 1-29)
CJC-1295 is a synthetic analog of growth hormone-releasing h...
Ipamorelin
Ipamorelin is a growth hormone secretagogue that selectively...
GHRP-2 (Pralmorelin)
GHRP-2 is a synthetic growth hormone-releasing peptide that ...
GHRP-6
GHRP-6 is a first-generation growth hormone-releasing peptid...
Hexarelin
Hexarelin is a synthetic growth hormone-releasing peptide (G...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.